These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30058933)

  • 1. Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action.
    Schernthaner-Reiter MH; Schernthaner G
    Expert Rev Endocrinol Metab; 2016 May; 11(3):281-296. PubMed ID: 30058933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
    Dokken B
    J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
    Dejager S; Schweizer A
    Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating incretin-based therapies for population-based health care.
    Calabrese D
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.
    Pratley RE; Cersosimo E
    Clin Diabetes; 2017 Jul; 35(3):141-153. PubMed ID: 28761216
    [No Abstract]   [Full Text] [Related]  

  • 17. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
    Kawanami D; Matoba K; Sango K; Utsunomiya K
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.
    Lo MC; Lansang MC
    Am J Ther; 2013; 20(6):638-53. PubMed ID: 20838206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.